tradingkey.logo
tradingkey.logo
Buscar

ADMA Biologics Inc

ADMA
Añadir a la lista de seguimiento
8.610USD
+0.240+2.87%
Cierre 07/01, 16:00ETCotizaciones retrasadas 15 min
2.00BCap. mercado
12.38P/E TTM

Más Datos de ADMA Biologics Inc Compañía

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Información de ADMA Biologics Inc

Símbolo de cotizaciónADMA
Nombre de la empresaADMA Biologics Inc
Fecha de salida a bolsaOct 17, 2013
Director ejecutivoGrossman (Adam S)
Número de empleados677
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 17
Dirección465 State Route 17
CiudadRAMSEY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal07446
Teléfono12014785552
Sitio Webhttps://www.admabiologics.com/
Símbolo de cotizaciónADMA
Fecha de salida a bolsaOct 17, 2013
Director ejecutivoGrossman (Adam S)

Ejecutivos de ADMA Biologics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%
Dr. Young T. Kwon, Ph.D.
Dr. Young T. Kwon, Ph.D.
Independent Director
Independent Director
--
--
Ms. Alison C. Finger
Ms. Alison C. Finger
Independent Director
Independent Director
--
--
Ms. Kaitlin Kestenberg
Ms. Kaitlin Kestenberg
Chief Operating Officer, Senior Vice President - Compliance
Chief Operating Officer, Senior Vice President - Compliance
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.94M
-33.49%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
602.30K
+5.21%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
175.82K
+10.98%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
-12.24%
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
-98.17%
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
2.03K
-12280.23%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de ADMA Biologics Inc?

Los cinco principales accionistas de ADMA Biologics Inc son: Mr. Adam S. Grossman

¿Cuántas instituciones poseen acciones de ADMA Biologics Inc (ADMA)?

A fecha de 2026Q1, 784 instituciones poseen acciones de ADMA Biologics Inc, con un valor de mercado combinado de aproximadamente 218.01M, lo que representa el 94.06% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -33855143.00.